Formulations and Methods for Contemporaneous Stabilization of Active Proteins During Spray Drying and Storage

Patent metadata

Field	Value
Publication number	US-2022040110-A1
Application number	US-202117508904-A
Country	US
Kind code	A1
Filing date	Oct 22, 2021
Priority date	Sep 19, 2014
Publication date	Feb 10, 2022
Grant date	—

Abstract

A method of treatment of plasma with a physiologically compatible spray dry stable acidic substance (SDSAS) prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compostions related to plasma dried by the methods of the present invention.

First claim

What is claimed is:

1 ) A method of producing a formulated plasma for drying, the method comprising:
a) combining one or more stable acidic substances with plasma, wherein the concentration of the stable acidic substance is in a range between about 0.001 mmol/ml and about 0.050 mmol/ml, wherein said one or more stable acidic substances is an acid or acidic salt that effectuates a pH, to thereby create a formulated plasma.

2 ) The method of claim 1 , wherein the method further comprises drying said formulated plasma in a plasma drying system to thereby obtain a dried formulated plasma.

3 ) The method of claim 1 , wherein said formulated plasma has a pH of about 5.5 to about 7.2.

4 ) The method of claim 1 , wherein the pH of the plasma is known prior to addition of said one or more stable acidic substances and the amount of said one or more stable acidic substances to be added plasma is determined based on the known pH of said plasma.

5 ) The method of claim 1 , wherein said one or more stable acidic substances is physiologically suitable for addition to plasma being dried or physiologically suitable for subjects into which reconstituted plasma is transfused.

6 ) The method of claim 1 , wherein the one or more stable acidic substances is selected from the group consisting of ascorbic acid, citric acid, gluconic acid, lactic acid, glycine hydrochloride, monosodium citrate, oxalic acid, halogenated acetic acids, arene sulfonic acids, molybdic acid, phosphotungstic acid, tungstic acid, chromic acid, sulfamic acid and any combination thereof.

7 ) The method of claim 1 , wherein citric acid is added to the plasma to increase citrate concentration by 7.4 mM.

8 ) A method of drying plasma, the method comprising:
a) combining one or more stable acidic substances and plasma, wherein the concentration of the stable acidic substance is in a range between about 0.001 mmol/ml and about 0.050 mmol/ml, wherein said one or more stable acidic substances is an acid or acidic salt that effectuates a pH, to thereby create a formulated plasma; and b) drying said formulated plasma in a plasma drying system to thereby obtain dried formulated plasma.

9 ) The method of claim 8 , wherein the when the dried formulated plasma is stable at ambient temperature for at least 7 days.

10 ) The method of claim 8 , wherein dried formulated plasma is stored for at least two weeks.

11 ) The method of claim 8 , wherein the dried formulated plasma is stored under refrigeration, at ambient temperature or at a higher temperature.

12 ) The method of claim 8 , wherein the dried formulated plasma has a moisture content of between about 2%-10%.

13 ) The method of claim 8 , wherein when combining the plasma with the one or more stable acidic substances occurs up to 30 minutes before drying.

14 ) The method of claim 8 , wherein when combining the plasma with the one or more stable acidic substances occurs immediately prior to or contemporaneously with drying.

15 ) A method of producing plasma suitable for transfusion into a recipient, the method comprising:
a) combining one or more stable acidic substances and plasma, wherein the concentration of the stable acidic substance is in a range between about 0.001 mmol/ml and about 0.050 mmol/ml, wherein said one or more stable acidic substances is an acid or acidic salt that effectuates a pH, to thereby create a formulated plasma; b) drying said formulated plasma in a plasma drying system to thereby obtain dried formulated plasma; and c) reconstituting the dried formulated plasma to thereby obtain reconstituted plasma suitable for transfusion into a recipient.

16 ) The method of claim 15 , wherein the reconstituted plasma has a pH of about 6.8 to about 7.6.

17 ) The method of claim 16 , wherein when the reconstituted plasma has a physiological pH.

18 ) The method of claim 15 , wherein said plasma comprises CPD (citrate phosphate dextrose solution) plasma or is WB (whole blood) plasma.

19 ) The method of claim 15 , wherein the reconstitution solution comprises a substance selected from the group consisting of: sterile water, sodium bicarbonate, disodium phosphate, and glycine sodium hydroxide.

20 ) The method of claim 15 , wherein von Willebrand factor activity from reconstituted plasm a is between about 5 and about 40 percentage points greater than the von Willebrand factor activity obtained from reconstituted plasm a that has been not undergone formulation with one or more stable acidic substances.

21 ) The method of claim 20 , wherein von Willebrand factor activity from reconstituted plasma is between about 10 and about 35 percentage points greater than the von Willebrand factor activity obtained from reconstituted plasm a that has been not undergone formulation with one or more stable acidic substances.

22 ) The method of claim 15 , further comprising measuring activity of Factors V, VII, VIII and IX or any combination thereof to determine stability of the reconstituted plasma.

23 ) A method of producing plasma suitable for transfusion into a recipient, the method comprising:
a) combining one or more stable acidic substances and plasma, wherein the concentration of the stable acidic substance is in a range between about 0.001 mmol/ml and about 0.050 mmol/ml, wherein said one or more stable acidic substances is an acid or acidic salt that effectuates a pH, to thereby create a formulated plasma; b) drying said formulated plasma in a plasma drying system to thereby obtain dried formulated plasma; c) storing the dried formulated plasma; and d) reconstituting the dried formulated plasma to thereby obtain reconstituted plasma suitable for transfusion into a recipient.

24 ) The method of claim 23 , wherein dried formulated plasma is stored for at least two weeks.

25 ) The method of claim 23 , wherein the dried formulated plasma is stored under refrigeration, at ambient temperature or at a higher temperature.

26 ) A method of producing dried formulated plasma, the method comprising providing:
a) plasma, b) one or more physiologically compatible stable acidic substances, wherein said one or more stable acidic substances is an acid or acidic salt that effectuates a pH and is physiologically suitable for addition to plasma being dried or physiologically suitable for subjects into which reconstituted plasma is transfused, wherein the concentration of the stable acidic substance is in a range between about 0.001 and about 0.050 mmol/ml, and wherein when plasma and one or more stable acidic substances are combined, the combination creates a formulated plasma, and c) a plasma drying system for drying the formulated plasma to thereby create a dried formulated plasma.

27 ) The method of claim 26 , wherein said formulated plasma has a pH of about 5.5 to about 7.2.

28 ) The method of claim 26 , wherein the pH of the plasma is known prior to addition of said one or more stable acidic substances and the amount of said one or more stable acidic substances to be added plasma is determined based on the known pH of said plasma.

29 ) The method of claim 26 , wherein the one or more stable acidic substances is selected from the group consisting of ascorbic acid, citric acid, gluconic acid, lactic acid, glycine hydrochloride, monosodium citrate, oxalic acid, halogenated acetic acids, arene sulfonic acids

Assignees

• Velico Medical Inc

Inventors

• Liu Qiyong Peter
• Cui Junqing
• Lucien Rud Karly
• Carney Ryan
• Sohn Jihae
• Arya Michelle

Classifications

• A61K9/1688 Primary

  resulting in pure drug agglomerate optionally containing up to 5% of excipient · CPC title

• F26B3/06

  the gas or vapour flowing through the materials or objects to be dried (F26B3/14 takes precedence) · CPC title

• F26B3/12

  in the form of a spray {, i.e. sprayed or dispersed emulsions or suspensions (spray drying of solutions B01D1/18)} · CPC title

• B65D51/30

  for desiccators · CPC title

• B65D81/266

  for absorbing gases, e.g. oxygen absorbers or desiccants (B65D51/244, B65D51/30 take precedence) · CPC title